Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Collaboration with world-renowned research centre to accelerate development of exosome therapies for rare diseases

3d illustration of cells secreting exosomes

Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, is pleased to announce the launch of a collaboration focused on rare diseases with the University of Oxford’s Oxford-Harrington Rare Disease Centre embedded within the Department of Paediatrics. The collaboration will run over three years and will capitalise on the world-class exosome research environment in Oxford, leveraging exosome therapeutics expertise and resources from both Evox and the University to drive innovation within rare disease drug development.

The Oxford-Harrington Rare Disease Centre – an affiliation between the University of Oxford and Harrington Discovery Institute – is a global leader in cutting-edge rare disease translational research. Through this collaboration, the parties will stimulate and support innovative approaches to identify and develop exosome therapeutics for the treatment of rare diseases. The collaboration also acts as a platform for the acceleration of translational exosome therapeutics research projects and seeks to build a strong cohort of scientists with in-depth knowledge of the exosome drug discovery process from both the academic and industrial perspective.

We are very pleased to be collaborating with a world-class institute like the Oxford-Harrington Rare Disease Centre on exosomes and their application to the treatment of life-threatening rare diseases. In bringing together our expertise, we can maximise the potential of our exciting technology to bring more options to patients struggling with rare diseases. - Dr Antonin de Fougerolles, Chief Executive Officer of Evox

Exosome therapeutics have the potential to significantly alter the landscape of rare disease treatment for the better. We are delighted to have entered into this collaboration with Evox, a leader in the field, to explore this area. We will look to leverage our joint resources and scientific expertise to identify exciting new treatment options. - Professor Georg Holländer, Head of Department, Department of Paediatrics

Similar stories

Urgent need for COVID-19 vaccine equity: UN-Oxford research

COVID-19 vaccine programmes are expected to cost poorer countries an additional 56.6% on health budgets, compared with just 0.8% on wealthy countries’ health expenditure, according to new data from the United Nations Development Programme (UNDP), the World Health Organisation (WHO) and the University of Oxford.

Difficulty hearing speech could be a risk factor for dementia

A new study led by University of Oxford researchers on over 82,000 participants has shown that difficulty hearing spoken conversations is associated with up to 91% increased risk of dementia.

Red and processed meat linked to increased risk of heart disease, Oxford study shows

Largest review of all large-scale studies to date finds red and processed meat increase the risk of heart disease.

How did people in Europe and SE Asia experience the first COVID-19 wave?

An international team, led by Phaik Yeong Cheah, conducted an anonymous online survey from May-June 2020, asking 5,058 people in Thailand, Malaysia, United Kingdom, Italy and Slovenia to share their experiences. Anne Osterrieder and colleagues in the Centre for Tropical Medicine & Global Health (Nuffield Department of Medicine) report the unequal impacts of public health measures, and the prevalence of ‘fake news’.